INS and metabolic dysfunction-associated steatotic liver disease: Implying that down regulation of ACACB could reduce hepatic fat content, which in turn would improve hepatic insulin sensitivity in NAFLD due to increased hepatic mitochondrial oxidation and reduced de novo lipogenesis.